 CRS Grade Supportive Care Tocilizumab Steroids Follow up
 Grade 2:  Symptoms require and respond to moderate intervention  Oxygen requirement <40% FiO2 or hypotension responsive to fluids or low dose of one vasopressora or Grade 2 organ toxicityb  Continuous cardiac telemetry and pulse oximetry as indicated  IV fluids bolus for hypotension withCCI  Vasopressor support for hypotension not responsive to IV fluids  Supplemental oxygen as indicated  Tocilizumab: 8mg/kg over 1 hour (not to exceed 800 mg)  Repeat tocilizumab every 4 to 6 hours as needed if not response to IV fluids or increasing supplemental oxygen; maximum of 3 doses in a 24-hour period.  Maximum total of 4 doses if no clinical improvement in the signs and symptoms of CRS  Dexamethasone CCI Improving:  Discontinue tocilizumab  Taper corticosteroids Not Improving:  Manage as Grade 3 (below)
 Grade 3:  Symptoms require and respond to aggressive intervention  Oxygen requirement ≥ 40% FiO2 or hypotension requiring high-dose or multiple vasopressorsa or Grade 3 organ toxicity or Grade 4 transaminitisb  Management in monitored care or intensive care unit  Per Grade 2  Methylprednisolone 1 mg/kg IV BIDc Improving:  Discontinue tocilizumab  Taper corticosteroids Not Improving:  Manage as Grade 4 (below)
 Grade 4:  Life-threatening symptoms  Requirements for ventilator support or continuous veno-venous hemodialysis (CVVHD)  Grade 4 organ toxicity (excluding transaminitis)b  Per Grade 3  Mechanical ventilation and/or renal replacement therapy may be required  Per Grade 2 High-dose corticosteroids:  Methylprednisolone 1000 mg/day CCI x 3 d ays Improving:  Discontinue tocilizumab  Taper corticosteroids Not improving:  Consider 1 gram BID to TID of methylprednisolone and other immunosuppressives (e.g. siltuximab) and anti-thymocyte globulin CCI
